TY - JOUR AU - Protzel, C. AU - Maruschke, M. AU - Hakenberg, O. W. PY - 2012 DA - 2012// TI - Epidemiology, aetiology and pathogenesis of renal cell carcinoma JO - Eur Urol Suppl VL - 11 UR - https://doi.org/10.1016/j.eursup.2012.05.002 DO - 10.1016/j.eursup.2012.05.002 ID - Protzel2012 ER - TY - JOUR AU - Ferlay, J. AU - Shin, H. R. AU - Bray, F. AU - Forman, D. AU - Mathers, C. AU - Parkin, D. M. PY - 2010 DA - 2010// TI - Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 JO - Int J Cancer VL - 127 UR - https://doi.org/10.1002/ijc.25516 DO - 10.1002/ijc.25516 ID - Ferlay2010 ER - TY - JOUR AU - Ljungberg, B. AU - Campbell, S. C. AU - Choi, H. Y. AU - Jacqmin, D. AU - Lee, J. E. AU - Weikert, S. PY - 2011 DA - 2011// TI - The epidemiology of renal cell carcinoma JO - Eur Urol VL - 60 UR - https://doi.org/10.1016/j.eururo.2011.06.049 DO - 10.1016/j.eururo.2011.06.049 ID - Ljungberg2011 ER - TY - JOUR AU - Atkins, M. AU - Regan, M. AU - McDermott, D. AU - Mier, J. AU - Stanbridge, E. AU - Youmans, A. PY - 2005 DA - 2005// TI - Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2019 DO - 10.1158/1078-0432.CCR-04-2019 ID - Atkins2005 ER - TY - JOUR AU - Bedke, J. AU - Stenzl, A. PY - 2013 DA - 2013// TI - Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now? JO - Expert Rev Anticancer Ther VL - 13 UR - https://doi.org/10.1586/14737140.2013.856761 DO - 10.1586/14737140.2013.856761 ID - Bedke2013 ER - TY - JOUR AU - Lamers, C. H. AU - Sleijfer, S. AU - van Steenbergen, S. AU - van Elzakker, P. AU - van Krimpen, B. AU - Groot, C. PY - 2013 DA - 2013// TI - Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity JO - Mol Ther VL - 21 UR - https://doi.org/10.1038/mt.2013.17 DO - 10.1038/mt.2013.17 ID - Lamers2013 ER - TY - JOUR AU - Bex, A. AU - Etto, T. AU - Vyth-Dreese, F. AU - Blank, C. AU - Griffioen, A. W. PY - 2012 DA - 2012// TI - Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? JO - Curr Oncol Rep VL - 14 UR - https://doi.org/10.1007/s11912-012-0229-9 DO - 10.1007/s11912-012-0229-9 ID - Bex2012 ER - TY - JOUR AU - Gross-Goupil, M. AU - Massard, C. AU - Ravaud, A. PY - 2012 DA - 2012// TI - Targeted therapies in metastatic renal cell carcinoma: overview of the past year JO - Curr Urol Rep VL - 13 UR - https://doi.org/10.1007/s11934-011-0232-y DO - 10.1007/s11934-011-0232-y ID - Gross-Goupil2012 ER - TY - JOUR AU - Genega, E. M. AU - Ghebremichael, M. AU - Najarian, R. AU - Fu, Y. AU - Wang, Y. AU - Argani, P. PY - 2010 DA - 2010// TI - Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade JO - Am J Clin Pathol VL - 134 UR - https://doi.org/10.1309/AJCPPPR57HNJMSLZ DO - 10.1309/AJCPPPR57HNJMSLZ ID - Genega2010 ER - TY - JOUR AU - Tostain, J. AU - Li, G. AU - Gentil-Perret, A. AU - Gigante, M. PY - 2010 DA - 2010// TI - Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2010.07.020 DO - 10.1016/j.ejca.2010.07.020 ID - Tostain2010 ER - TY - JOUR AU - Svastova, E. AU - Hulikova, A. AU - Rafajova, M. AU - Zat’ovicova, M. AU - Gibadulinova, A. AU - Casini, A. PY - 2004 DA - 2004// TI - Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH JO - FEBS Lett VL - 577 UR - https://doi.org/10.1016/j.febslet.2004.10.043 DO - 10.1016/j.febslet.2004.10.043 ID - Svastova2004 ER - TY - JOUR AU - Swietach, P. AU - Patiar, S. AU - Supuran, C. T. AU - Harris, A. L. AU - Vaughan-Jones, R. D. PY - 2009 DA - 2009// TI - The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths JO - J Biol Chem VL - 284 UR - https://doi.org/10.1074/jbc.M109.006478 DO - 10.1074/jbc.M109.006478 ID - Swietach2009 ER - TY - JOUR AU - Bui, M. H. AU - Seligson, D. AU - Han, K. R. AU - Pantuck, A. J. AU - Dorey, F. J. AU - Huang, Y. PY - 2003 DA - 2003// TI - Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy JO - Clin Cancer Res VL - 9 ID - Bui2003 ER - TY - JOUR AU - Chiche, J. AU - Ilc, K. AU - Laferriere, J. AU - Trottier, E. AU - Dayan, F. AU - Mazure, N. M. PY - 2009 DA - 2009// TI - Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2470 DO - 10.1158/0008-5472.CAN-08-2470 ID - Chiche2009 ER - TY - JOUR AU - McIntyre, A. AU - Patiar, S. AU - Wigfield, S. AU - Li, J. L. AU - Ledaki, I. AU - Turley, H. PY - 2012 DA - 2012// TI - Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1877 DO - 10.1158/1078-0432.CCR-11-1877 ID - McIntyre2012 ER - TY - JOUR AU - McDonald, P. C. AU - Winum, J. Y. AU - Supuran, C. T. AU - Dedhar, S. PY - 2012 DA - 2012// TI - Recent developments in targeting carbonic anhydrase IX for cancer therapeutics JO - Oncotarget VL - 3 UR - https://doi.org/10.18632/oncotarget.422 DO - 10.18632/oncotarget.422 ID - McDonald2012 ER - TY - JOUR AU - Schwaab, T. AU - Ernstoff, M. S. PY - 2011 DA - 2011// TI - Therapeutic vaccines in renal cell carcinoma JO - Therapy VL - 4 UR - https://doi.org/10.2217/thy.11.40 DO - 10.2217/thy.11.40 ID - Schwaab2011 ER - TY - JOUR AU - Shuch, B. AU - Li, Z. AU - Belldegrun, A. S. PY - 2008 DA - 2008// TI - Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies JO - BJU Int VL - 101 UR - https://doi.org/10.1111/j.1464-410X.2008.07645.x DO - 10.1111/j.1464-410X.2008.07645.x ID - Shuch2008 ER - TY - JOUR AU - Van Poppel, H. AU - Joniau, S. AU - Van Gool, S. W. PY - 2009 DA - 2009// TI - Vaccine therapy in patients with renal cell carcinoma JO - Eur Urol VL - 55 UR - https://doi.org/10.1016/j.eururo.2009.01.043 DO - 10.1016/j.eururo.2009.01.043 ID - Van Poppel2009 ER - TY - JOUR AU - Bleumer, I. AU - Oosterwijk, E. AU - Oosterwijk-Wakka, J. C. AU - Voller, M. C. AU - Melchior, S. AU - Warnaar, S. O. PY - 2006 DA - 2006// TI - A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma JO - J Urol VL - 175 UR - https://doi.org/10.1016/S0022-5347(05)00040-6 DO - 10.1016/S0022-5347(05)00040-6 ID - Bleumer2006 ER - TY - JOUR AU - Petrul, H. M. AU - Schatz, C. A. AU - Kopitz, C. C. AU - Adnane, L. AU - McCabe, T. J. AU - Trail, P. PY - 2012 DA - 2012// TI - Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79–4620 targeting human carbonic anhydrase 9 JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0523 DO - 10.1158/1535-7163.MCT-11-0523 ID - Petrul2012 ER - TY - JOUR AU - Siebels, M. AU - Rohrmann, K. AU - Oberneder, R. AU - Stahler, M. AU - Haseke, N. AU - Beck, J. PY - 2011 DA - 2011// TI - A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX (R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients JO - World J Urol VL - 29 UR - https://doi.org/10.1007/s00345-010-0570-2 DO - 10.1007/s00345-010-0570-2 ID - Siebels2011 ER - TY - JOUR AU - Xu, C. AU - Lo, A. AU - Yammanuru, A. AU - Tallarico, A. S. AU - Brady, K. AU - Murakami, A. PY - 2010 DA - 2010// TI - Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology JO - PLoS One VL - 5 UR - https://doi.org/10.1371/journal.pone.0009625 DO - 10.1371/journal.pone.0009625 ID - Xu2010 ER - TY - JOUR AU - Oosterwijk-Wakka, J. C. AU - Boerman, O. C. AU - Mulders, P. F. AU - Oosterwijk, E. PY - 2013 DA - 2013// TI - Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma JO - Int J Mol Sci VL - 14 UR - https://doi.org/10.3390/ijms140611402 DO - 10.3390/ijms140611402 ID - Oosterwijk-Wakka2013 ER - TY - JOUR AU - Eisen, T. AU - Sternberg, C. N. AU - Robert, C. AU - Mulders, P. AU - Pyle, L. AU - Zbinden, S. PY - 2012 DA - 2012// TI - Targeted therapies for renal cell carcinoma: review of adverse event management strategies JO - J Natl Cancer Inst VL - 104 UR - https://doi.org/10.1093/jnci/djr511 DO - 10.1093/jnci/djr511 ID - Eisen2012 ER - TY - STD TI - Belldegrun AS, Chamie K, Kloepfer P, Fall B, Bevan P, Störkel S, et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—results and implications for adjuvant clinical trials. J Clin Oncol. 2013; 31 (Supplement, abstr 4507). ID - ref26 ER - TY - JOUR AU - Tentler, J. J. AU - Tan, A. C. AU - Weekes, C. D. AU - Jimeno, A. AU - Leong, S. AU - Pitts, T. M. PY - 2012 DA - 2012// TI - Patient-derived tumour xenografts as models for oncology drug development JO - Nat Rev Clin Oncol VL - 9 UR - https://doi.org/10.1038/nrclinonc.2012.61 DO - 10.1038/nrclinonc.2012.61 ID - Tentler2012 ER - TY - JOUR AU - Lo, A. S. -. Y. AU - Xu, C. AU - Murakami, A. AU - Marasco, W. A. PY - 2014 DA - 2014// TI - Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor JO - Mol Ther — Oncolytics VL - 1 UR - https://doi.org/10.1038/mto.2014.3 DO - 10.1038/mto.2014.3 ID - Lo2014 ER - TY - JOUR AU - Svastova, E. AU - Witarski, W. AU - Csaderova, L. AU - Kosik, I. AU - Skvarkova, L. AU - Hulikova, A. PY - 2012 DA - 2012// TI - Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain JO - J Biol Chem VL - 287 UR - https://doi.org/10.1074/jbc.M111.286062 DO - 10.1074/jbc.M111.286062 ID - Svastova2012 ER - TY - JOUR AU - Chang, D. K. AU - Sui, J. AU - Geng, S. AU - Muvaffak, A. AU - Bai, M. AU - Fuhlbrigge, R. C. PY - 2012 DA - 2012// TI - Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-12-0278 DO - 10.1158/1535-7163.MCT-12-0278 ID - Chang2012 ER - TY - JOUR AU - Bailey, A. AU - McDermott, D. F. PY - 2013 DA - 2013// TI - Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics JO - Cancer J VL - 19 UR - https://doi.org/10.1097/PPO.0b013e31829e3153 DO - 10.1097/PPO.0b013e31829e3153 ID - Bailey2013 ER - TY - JOUR AU - Moore, G. L. AU - Chen, H. AU - Karki, S. AU - Lazar, G. A. PY - 2010 DA - 2010// TI - Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions JO - mAbs VL - 2 UR - https://doi.org/10.4161/mabs.2.2.11158 DO - 10.4161/mabs.2.2.11158 ID - Moore2010 ER - TY - JOUR AU - Sivanand, S. AU - Pena-Llopis, S. AU - Zhao, H. AU - Kucejova, B. AU - Spence, P. AU - Pavia-Jimenez, A. PY - 2012 DA - 2012// TI - A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma JO - Sci Transl Med VL - 4 UR - https://doi.org/10.1126/scitranslmed.3003643 DO - 10.1126/scitranslmed.3003643 ID - Sivanand2012 ER - TY - JOUR AU - Grisanzio, C. AU - Seeley, A. AU - Chang, M. AU - Collins, M. AU - Di Napoli, A. AU - Cheng, S. C. PY - 2011 DA - 2011// TI - Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients JO - J Pathol VL - 225 UR - https://doi.org/10.1002/path.2929 DO - 10.1002/path.2929 ID - Grisanzio2011 ER - TY - JOUR AU - Brehm, M. A. AU - Shultz, L. D. PY - 2012 DA - 2012// TI - Human allograft rejection in humanized mice: a historical perspective JO - Cell Mol Immunol VL - 9 UR - https://doi.org/10.1038/cmi.2011.64 DO - 10.1038/cmi.2011.64 ID - Brehm2012 ER - TY - JOUR AU - Montoya, C. J. AU - Pollard, D. AU - Martinson, J. AU - Kumari, K. AU - Wasserfall, C. AU - Mulder, C. B. PY - 2007 DA - 2007// TI - Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11 JO - Immunology VL - 122 UR - https://doi.org/10.1111/j.1365-2567.2007.02647.x DO - 10.1111/j.1365-2567.2007.02647.x ID - Montoya2007 ER - TY - JOUR AU - Leibson, P. J. PY - 1997 DA - 1997// TI - Signal transduction during natural killer cell activation: inside the mind of a killer JO - Immunity VL - 6 UR - https://doi.org/10.1016/S1074-7613(00)80441-0 DO - 10.1016/S1074-7613(00)80441-0 ID - Leibson1997 ER - TY - JOUR AU - Clynes, R. AU - Takechi, Y. AU - Moroi, Y. AU - Houghton, A. AU - Ravetch, J. V. PY - 1998 DA - 1998// TI - Fc receptors are required in passive and active immunity to melanoma JO - Proc Natl Acad Sci U S A VL - 95 UR - https://doi.org/10.1073/pnas.95.2.652 DO - 10.1073/pnas.95.2.652 ID - Clynes1998 ER - TY - JOUR AU - Nimmerjahn, F. AU - Bruhns, P. AU - Horiuchi, K. AU - Ravetch, J. V. PY - 2005 DA - 2005// TI - FcgammaRIV: a novel FcR with distinct IgG subclass specificity JO - Immunity VL - 23 UR - https://doi.org/10.1016/j.immuni.2005.05.010 DO - 10.1016/j.immuni.2005.05.010 ID - Nimmerjahn2005 ER - TY - STD TI - Ravetch J, Nimmerjahn F. Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof. 2008. vol. EP2455100A2: pp. 1–262012:1–26. ID - ref40 ER - TY - JOUR AU - Ravetch, J. V. PY - 1997 DA - 1997// TI - Fc receptors JO - Curr Opin Immunol VL - 9 UR - https://doi.org/10.1016/S0952-7915(97)80168-9 DO - 10.1016/S0952-7915(97)80168-9 ID - Ravetch1997 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Murri-Plesko, M. T. AU - Hulikova, A. AU - Oosterwijk, E. AU - Scott, A. M. AU - Zortea, A. AU - Harris, A. L. PY - 2011 DA - 2011// TI - Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX JO - Eur J Pharmacol VL - 657 UR - https://doi.org/10.1016/j.ejphar.2011.01.063 DO - 10.1016/j.ejphar.2011.01.063 ID - Murri-Plesko2011 ER - TY - JOUR AU - Neri, D. AU - Supuran, C. T. PY - 2011 DA - 2011// TI - Interfering with pH regulation in tumours as a therapeutic strategy JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3554 DO - 10.1038/nrd3554 ID - Neri2011 ER - TY - JOUR AU - Supuran, C. T. PY - 2008 DA - 2008// TI - Carbonic anhydrases: novel therapeutic applications for inhibitors and activators JO - Nat Rev Drug Discov VL - 7 UR - https://doi.org/10.1038/nrd2467 DO - 10.1038/nrd2467 ID - Supuran2008 ER - TY - JOUR AU - Karam, J. A. AU - Zhang, X. Y. AU - Tamboli, P. AU - Margulis, V. AU - Wang, H. AU - Abel, E. J. PY - 2011 DA - 2011// TI - Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma JO - Eur Urol VL - 59 UR - https://doi.org/10.1016/j.eururo.2010.11.043 DO - 10.1016/j.eururo.2010.11.043 ID - Karam2011 ER - TY - JOUR AU - Yuen, J. S. AU - Sim, M. Y. AU - Siml, H. G. AU - Chong, T. W. AU - Lau, W. K. AU - Cheng, C. W. PY - 2011 DA - 2011// TI - Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model JO - Br J Cancer VL - 104 UR - https://doi.org/10.1038/bjc.2011.55 DO - 10.1038/bjc.2011.55 ID - Yuen2011 ER - TY - JOUR AU - Chen, Q. AU - Khoury, M. AU - Chen, J. PY - 2009 DA - 2009// TI - Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0912274106 DO - 10.1073/pnas.0912274106 ID - Chen2009 ER - TY - JOUR AU - Huntington, N. D. AU - Legrand, N. AU - Alves, N. L. AU - Jaron, B. AU - Weijer, K. AU - Plet, A. PY - 2009 DA - 2009// TI - IL-15 trans-presentation promotes human NK cell development and differentiation in vivo JO - J Exp Med VL - 206 UR - https://doi.org/10.1084/jem.20082013 DO - 10.1084/jem.20082013 ID - Huntington2009 ER - TY - JOUR AU - Shultz, L. D. AU - Ishikawa, F. AU - Greiner, D. L. PY - 2007 DA - 2007// TI - Humanized mice in translational biomedical research JO - Nat Rev Immunol VL - 7 UR - https://doi.org/10.1038/nri2017 DO - 10.1038/nri2017 ID - Shultz2007 ER - TY - JOUR AU - Hyrsl, L. AU - Zavada, J. AU - Zavadova, Z. AU - Kawaciuk, I. AU - Vesely, S. AU - Skapa, P. PY - 2009 DA - 2009// TI - Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract JO - Neoplasma VL - 56 UR - https://doi.org/10.4149/neo_2009_04_29 DO - 10.4149/neo_2009_04_29 ID - Hyrsl2009 ER - TY - JOUR AU - King, M. AU - Pearson, T. AU - Shultz, L. D. AU - Leif, J. AU - Bottino, R. AU - Trucco, M. PY - 2008 DA - 2008// TI - A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene JO - Clin Immunol VL - 126 UR - https://doi.org/10.1016/j.clim.2007.11.001 DO - 10.1016/j.clim.2007.11.001 ID - King2008 ER - TY - JOUR AU - Serreze, D. V. AU - Leiter, E. H. PY - 1994 DA - 1994// TI - Genetic and pathogenic basis of autoimmune diabetes in NOD mice JO - Curr Opin Immunol VL - 6 UR - https://doi.org/10.1016/0952-7915(94)90011-6 DO - 10.1016/0952-7915(94)90011-6 ID - Serreze1994 ER - TY - JOUR AU - Dunkelberger, J. R. AU - Song, W. C. PY - 2010 DA - 2010// TI - Complement and its role in innate and adaptive immune responses JO - Cell Res VL - 20 UR - https://doi.org/10.1038/cr.2009.139 DO - 10.1038/cr.2009.139 ID - Dunkelberger2010 ER - TY - STD TI - Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. ID - ref55 ER - TY - STD TI - Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. ID - ref56 ER - TY - JOUR AU - Thompson, R. H. AU - Kuntz, S. M. AU - Leibovich, B. C. AU - Dong, H. AU - Lohse, C. M. AU - Webster, W. S. PY - 2006 DA - 2006// TI - Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-4303 DO - 10.1158/0008-5472.CAN-05-4303 ID - Thompson2006 ER - TY - JOUR AU - Trastour, C. AU - Benizri, E. AU - Ettore, F. AU - Ramaioli, A. AU - Chamorey, E. AU - Pouyssegur, J. PY - 2007 DA - 2007// TI - HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome JO - Int J Cancer VL - 120 UR - https://doi.org/10.1002/ijc.22436 DO - 10.1002/ijc.22436 ID - Trastour2007 ER - TY - JOUR AU - Generali, D. AU - Berruti, A. AU - Brizzi, M. P. AU - Campo, L. AU - Bonardi, S. AU - Wigfield, S. PY - 2006 DA - 2006// TI - Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-2690 DO - 10.1158/1078-0432.CCR-05-2690 ID - Generali2006 ER - TY - JOUR AU - Bartosova, M. AU - Parkkila, S. AU - Pohlodek, K. AU - Karttunen, T. J. AU - Galbavy, S. AU - Mucha, V. PY - 2002 DA - 2002// TI - Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2 JO - J Pathol VL - 197 UR - https://doi.org/10.1002/path.1120 DO - 10.1002/path.1120 ID - Bartosova2002 ER - TY - JOUR AU - Wykoff, C. C. AU - Beasley, N. AU - Watson, P. H. AU - Campo, L. AU - Chia, S. K. AU - English, R. PY - 2001 DA - 2001// TI - Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast JO - Am J Pathol VL - 158 UR - https://doi.org/10.1016/S0002-9440(10)64048-5 DO - 10.1016/S0002-9440(10)64048-5 ID - Wykoff2001 ER -